(Reuters) -GSK's CEO Emma Walmsley will step down at the end of the year and be replaced by insider Luke Miels, the drugmaker said on Monday, a surprise switch as the British firm looks to rev up its ...

GSK said Chief Executive Emma Walmsley would step down and be succeeded by commercial chief Luke Miels, as the drugmaker works to replenish its product lineup. Walmsley will step down at the end of ...

Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. LONDON — GSK on Monday said that ...

Dame Emma Walmsley, CEO of GSK arrives for a business roundtable attended by President Donald Trump and Britain's Prime Minister Keir Starmer at Chequers near ...

GSK CEO Emma Walmsley will be stepping aside after nine years. Shares of GSK rallied on Monday after the U.K. pharmaceutical giant turned to an insider to become its next CEO. Luke Miels, chief ...

The pharma hasn’t yet revealed what kind of job cuts might be involved in the plan, which will help it absorb the coming loss of patents important to its HIV drug franchise.

GSK chief executive Emma Walmsley will be replaced by chief commercial officer Luke Miels on January 1 – Copyright GETTY IMAGES NORTH AMERICA/AFP Kayla Bartkowski ...

GlaxoSmithKline Plc Chief Executive Officer Emma Walmsley talks about developing a Covid vaccine, who would get it, the public perception of the pharmaceutical industry, and why she doesn't let her ...

LONDON — GSK Chief Executive Emma Walmsley, the first woman to lead a major pharmaceutical company, will step down Dec. 31 after more than eight years at the head of the London-based drugmaker.